Molecular imaging of nuclear factor-Y transcriptional activity maps proliferation sites in live animals by F. Goeman et al.
Volume 23 April 15, 2012 1467 
MBoC | ARTICLE
Molecular imaging of nuclear factor-Y 
transcriptional activity maps proliferation sites 
in live animals
Frauke Goemana,*,†, Isabella Mannia,*, Simona Artusoa,*, Balaji Ramachandranb, Gabriele Toiettac, 
Gianluca Bossia, Gianpaolo Randob, Chiara Cencionid, Sabrina Germonie, Stefania Strainoc, 
Maurizio C. Capogrossic, Silvia Bacchettia, Adriana Maggib, Ada Sacchia, Paolo Cianab, and 
Giulia Piaggioa
aExperimental Oncology Department, Istituto Regina Elena, 00158 Rome, Italy; bDepartment of Pharmacological 
Sciences, University of Milan, 20133 Milan, Italy; cLaboratorio di Patologia Vascolare, Istituto Dermopatico 
dell’Immacolata, IRCCS, 00167 Rome, Italy; dLaboratorio di Biologia Vascolare e Medicina Rigenerativa, Centro 
Cardiologico, Monzino-IRCCS, 20138 Milan, Italy; eSAFU, Istituto Regina Elena, 00158 Rome, Italy
ABSTRACT In vivo imaging involving the use of genetically engineered animals is an innovative 
powerful tool for the noninvasive assessment of the molecular and cellular events that are of-
ten targets of therapy. On the basis of the knowledge that the activity of the nuclear factor-Y 
(NF-Y) transcription factor is restricted in vitro to proliferating cells, we have generated a trans-
genic reporter mouse, called MITO-Luc (for mitosis-luciferase), in which an NF-Y–dependent 
promoter controls luciferase expression. In these mice, bioluminescence imaging of NF-Y activ-
ity visualizes areas of physiological cell proliferation and regeneration during response to injury. 
Using this tool, we highlight for the first time a role of NF-Y activity on hepatocyte proliferation 
during liver regeneration. MITO-Luc reporter mice should facilitate investigations into the in-
volvement of genes in cell proliferation and provide a useful model for studying aberrant pro-
liferation in disease pathogenesis. They should be also useful in the development of new anti/
proproliferative drugs and assessment of their efficacy and side effects on nontarget tissues.
INTRODUCTION
Nuclear factor-Y (NF-Y) is a trimeric activator composed of NF-YA, 
NF-YB, and NF-YC subunits, all of which are required for DNA bind-
ing. The three subunits are highly conserved in evolution and repre-
sent the complex recognizing the CCAAT motif (Dolfini et al., 2009). 
The NF-Y complex supports proliferation regulating the basal tran-
scription of regulatory genes responsible for cell cycle progression, 
among which are mitotic cyclin complexes (Bolognese et al., 1999; 
Caretti et al., 1999; Farina et al., 1999; Sciortino et al., 2001; Gurtner 
et al., 2003, 2008; Di Agostino et al., 2006). We provide evidence 
that NF-Y plays a central role in the switch from proliferation to dif-
ferentiation. In proliferating skeletal muscle cells, all subunits are 
expressed, whereas in terminally differentiated cells, NF-YA is unde-
tectable, and the suppression of NF-Y function is crucial for the inhi-
bition of multiple cell cycle genes and the induction of early muscle 
differentiation markers (Farina et al., 1999; Gurtner et al., 2008; 
Manni et al., 2008). In line with this, conditional deletion of NF-YA in 
mice causes early embryo lethality, demonstrating that NF-Y is es-
sential for early mouse development (Bhattacharya et al., 2003). 
Moreover, it has been described that inhibition of NF-Y function 
leads to defects in embryonic (ES) and hematopoietic (HSC) stem 
cell proliferation (Grskovic et al., 2007; Bungartz et al., 2012).
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we detected high luciferase activity in the vertebral column, ster-
num, spleen, testis, femur, and skull as expected, based on in vivo 
analysis. Several tissues (e.g., lung, brain, heart, aorta, skeletal mus-
cle, liver, and kidney) did not emit light. All the tissues noted were 
imaged with the same color scale bar. In these experimental condi-
tions, the intestine, stomach, uterus, and ovaries also did not emit 
light. Interestingly, using a more stringent color scale bar, we also 
observed luciferase activity along these tissues, suggesting that 
their lower luminescence in vivo was indeed due to tissue penetra-
tion light loss. To demonstrate that these signals were specific, we 
imaged the spleen and the lung with the same color scale bar as 
negative and positive tissues, respectively (Figure S2B).
To further verify tissue distribution of luciferase, we measured en-
zymatic activity in homogenates of 21 different tissues from both male 
and female 6- to -8-wk-old mice (Figure S3). The in vitro results closely 
resembled those seen in vivo and ex vivo. Transgenic line #26 showed 
similar in vivo, ex vivo, and in vitro results but with lower intensities 
(unpublished data), due to its lower transgene copy number.
Bioluminescence imaging (BLI) strategies have recently been in-
corporated into animal research protocols, including those involving 
the use of genetically engineered animals. These tools offer the ad-
vantage of noninvasive in vivo assessment of the molecular and cel-
lular events that are often targets of therapy; as such, these events 
can be studied in individual animals over time. This reduces the 
number of animals required for a given study and improves the data 
set, as the temporal data allow for each animal to serve as its own 
internal control. For small rodents, such as mice, this noninvasive 
imaging technique allows detection of signals throughout the entire 
animal (Ciana et al., 2003; Signore et al., 2010).
In this paper, we present a new transgenic mouse model, MITO-
Luc (for mitosis-luciferase) reporter mice, in which we demonstrate 
that proliferation can be visualized noninvasively in vivo. We based 
our model on the rationale that NF-Y activity is exerted only in pro-
liferating cells. The transgenic mouse model we have developed 
harbors a strictly NF-Y–dependent promoter in front of a luciferase 
reporter, allowing us to monitor the NF-Y activity in a spatiotempo-
ral manner within the entire living organism. Using a dominant-neg-
ative protein for NF-Y, we reveal for the first time a possible involve-
ment of NF-Y activity in liver regeneration.
RESULTS
NF-Y–dependent cyclin B2 promoter fragment drives 
transcription in MITO-Luc mice
For the generation of the MITO-Luc reporter mice, we used a trans-
gene harboring the luciferase gene under control of an NF-Y–de-
pendent cyclin B2 promoter fragment as a sensor of NF-Y activity in 
vivo. To minimize the influence of the surrounding chromatin status 
at the integration site, we flanked this construct with insulators that 
were reported to overcome position effects to a large extent (Ciana 
et al., 2003; Figure 1a). As a control, we cloned the same promoter 
regions with all CCAAT boxes mutated (CCAAT mutated into 
TTACT). To test the functionality of these constructs, we performed 
transient transfections in murine C2C12 (Figure 1b) and NIH 3T3 
cells (unpublished data). These experiments revealed that the muta-
tion of the CCAAT boxes led to a significant reduction of luciferase 
units, showing the dependency of this promoter construct on NF-Y 
activity. The transgene was injected in the pronucleus of fertilized 
C57BL/6xDBA/2 eggs using standard protocols (Hogan et al., 1994). 
We obtained three independent founder animals, of which two were 
fertile. Semi-quantitative PCR analysis with genomic DNA from tail 
biopsies showed clear differences in the transgene amount in the 
two lines, #10 and #26 (Supplemental Figure S1). We injected the 
luciferase substrate d-luciferin, into anesthetized transgenic mice 
and visualized luciferase activity with a charge-coupled device (CCD) 
camera (Signore et al., 2010). Both male and female mice were im-
aged in ventral and dorsal positions (Figure 1c). Light emission, al-
though to different extents, was detected in areas corresponding to 
femur, skull, sternum, vertebral column, and spleen, and it was equal 
in both genders for common tissues. In males, testes were also lumi-
nescent (Figure S2A).
In vivo imaging is carried out in two dimensions; thus the defini-
tion of the organ/tissue contributing to the photon emission is lim-
ited; furthermore, tissue penetration can cause some emitted light 
to be lost. Therefore we carried out ex vivo experiments in which we 
measured luciferase activity of dissected organs from the killed mice. 
The measurement of the enzyme activity was done by biolumines-
cence, exposing the dissected organ to the CCD camera. As seen in 
vivo, overall light emission was equal in both genders (unpublished 
data). As shown in Figure 1d, luciferase activity, as measured ex vivo, 
generally reproduces and extends what is observed in vivo. Indeed, 
FIGURE 1: NF-Y–dependent luciferase transcription in MITO-Luc 
mice. (a) Scheme of the transgene used. (b) C2C12 cells transiently 
transfected with the wild-type (white bar) or mutated (black bar) 
CCAAT (CCAAT versus TTACT) boxes. Transfection efficiency was 
normalized with cotransfected β-galactosidase expression vector 
(pCMV-lacZ). The error bars indicate the deviation of the mean of two 
experiments performed in triplicate. (c) BLI of representative 
MITO-Luc mice. The images were collected on 31 animals of each 
gender; one representative animal is shown. (d) Ex vivo BLI of positive 
and negative luciferase organs. After the animals were killed, the 
indicated organs were collected. Images of five animals for each 
gender were collected and one representative animal is shown. (c and 
d) Light emitted from the animal appears in pseudocolor scaling.
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The cellular distribution of NF-Y and lu-
ciferase was analyzed by immunohistochem-
istry (Figure 2d). Adjacent slices from testis, 
spleen, and, as a negative control, skeletal 
muscle, were stained with antibodies against 
NF-YA or luciferase. Immunoreactivity for 
both was clearly detected in testis and 
spleen, while no staining was observed in 
skeletal muscle. Both testis and spleen con-
tain proliferating cells, while postmitotic 
cells are the main constituents of skeletal 
muscles. To detect proliferating cells, we 
stained the slices with the antibody anti-
PCNA, an antigen expressed in proliferating 
cells and not in quiescent cells. As expected, 
PCNA is expressed in the proliferating germ 
cells and spermatogonium inside the semi-
niferous tubules of the testis, and in several 
cells in the spleen. Of note, cells expressing 
the proliferation marker PCNA contain high 
levels of NF-YA and luciferase, indicating 
that in live animals, as in cultured cells, the 
NF-Y complex is active in proliferating, but 
not in postmitotic, cells. Most notably, the 
results in Figures 1 and 2 point to the MITO-
Luc reporter mice as a powerful tool for visu-
alizing proliferation events in live animals.
Analysis of luciferase activity upon 
inhibition of proliferation in MITO-Luc 
mice
To further understand whether the luciferase 
activity does occur in proliferating cells, we 
treated MITO-Luc mice with 5-fluorouracil 
(5-FU), a well-known antiproliferative drug 
(Hofer et al., 2006). The main effects of 5-FU 
are on rapidly proliferating tissues, particu-
larly bone marrow. After 5 d of treatment, 
we collected bone marrow from MITO-Luc 
mice femurs and observed that the luciferase 
activity was strongly inhibited by the drug 
treatment (Figure 3a). This inhibition corre-
lates well with the inhibition of the S phase 
of bone marrow cell mediated by the drug 
treatment, as observed by fluorescence-ac-
tivated cell sorting (FACS) analysis (Figure 
3b). We next observed the effects of 5-FU in 
a long-term experiment. We monitored the 
drug effects over time, reimaging the same animal at various time 
points posttreatment. Representative images are shown at 5, 10, 15, 
23, 30, and 75 d posttreatment (Figure 3c). In the first 5 d after treat-
ment, we observed a significant decrease of luminescence over the 
entire body. Fifteen days later, we observed luminescence in the 
spleen, which indicated that proliferation was occurring in the tissue 
at that time, and it is already known that spleen cells proliferate at 
this time to repopulate the bone marrow. Whole-body luminescence 
was completely restored at 75 d posttreatment. It has been shown 
that ionizing irradiation of normal tissues leads to tissue damage 
through cell cycle arrest and apoptosis (Stone et al., 2003). Thus 
MITO-Luc mice were subjected to whole-body cesium γ-irradiation 
with sublethal doses of 3 and 5 Gy. Baseline images were obtained 
before treatment, and mice were then reimaged at various time points 
To demonstrate the dependence of luciferase expression on 
NF-Y transcriptional activity, we injected MITO-Luc mice intrave-
nously with an adenovirus expressing a dominant-negative mutant 
of NF-Y, dn-YA (Ad-dnYA), that impairs the DNA binding of the re-
sulting complex (Mantovani et al., 1994; Gurtner et al., 2008). This 
molecule is an NF-YA protein with a triple amino acid substitution in 
the DNA-binding domain that impairs its ability to bind DNA (Figure 
2a). It is still able to interact with an NF-YB/-YC dimer, but the result-
ing trimer is inactive in terms of CCAAT recognition (Figure 2b). Ad-
dnYA injection resulted in almost complete inhibition of luciferase 
activity in every body area after 2 d, returning to almost basal level 
at day 8 (Figures 2c and S4). These results definitely demonstrate 
that the luciferase gene is expressed in an NF-Y–dependent manner 
in every area of the MITO-Luc mice.
FIGURE 2: NF-Y–dependent luciferase transcription in MITO-Luc mice. (a) Scheme of the 
dominant-negative NF-YA protein (dn-YA). (b) The NF-Y subunits, A, B, and C, form a complex 
that binds DNA. dn-YA is still able to interact with the NF-YB/-YC dimer, but the resulting trimer 
is inactive in terms of DNA binding. (c) BLI of representative MITO-Luc mice before (pre) and 
after (days 2, 4, 6, 8) injection of an adenovirus vector expressing GFP (Ad-GFP) or Ad-dnYA. 
The experiments were conducted on nine animals per group. Light emitted from the animals 
appears in pseudocolor scaling. (d) Immunohistochemical analysis of NF-YA, luciferase (LUC), 
and PCNA in testis (40×; insets: 100×), spleen (100×), and skeletal muscle (60×) tissues from a 
representative MITO-Luc mouse.
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of DNA synthesis, and were then immunos-
tained for BrdU. As expected, 95% of the 
myoblasts incorporated BrdU, while myo-
tubes did not. As a control, myoblasts and 
myotubes were immunostained for muscle-
specific myosin heavy chain (MHC), a marker 
of terminal differentiation in skeletal muscle. 
As expected, the majority of the myotubes 
expressed MHC, while myoblasts did not. 
Next, mouse embryonic fibroblasts (MEFs) 
were isolated from MITO-Luc mice and, as 
shown in Figure 4d, luciferase activity was 
high in proliferating MEFs, but was shut 
down in quiescent MEFs. Moreover, activity 
was greatly down-regulated in MEFs at 24 h 
postinfection with Ad-dnYA (Figure S5). 
These results demonstrate that the luciferase 
gene is expressed in an NF-Y–dependent 
manner in proliferating cells isolated from 
MITO-Luc mice. Moreover, these results also 
give information about the leakage of the 
transgene. Indeed, both in myotubes and in 
quiescent fibroblasts the luciferase activity is 
very low, suggesting that the expression of 
the luciferase is not influenced by the sur-
rounding chromatin.
Luciferase activity is induced in 
MITO-Luc mouse tissues upon 
induction of proliferation
We asked whether it was possible to induce 
luciferase expression upon induction of pro-
liferation in MITO-Luc mice. Aberrant prolif-
eration represents an early occurring pre-
neoplastic event. We therefore induced formation of skin papillomas 
by local administration of 7,12-dimethylbenz(a)anthracene and phor-
bol ester 12-O-tetradecanoylphorbol-13 acetate (DMBA-TPA) to the 
skin of MITO-Luc mice. DMBA and TPA were put directly onto shaved 
ventral skin (Figure 5a), with DMBA applied once-weekly and TPA 
applied twice-weekly. Representative images are shown for 2, 4, 6, 
and 8 wk after the first DMBA treatment. We detected luminescence 
at the treated sites directly after the first DMBA application and dur-
ing the DMBA-TPA treatment period prior to tumor occurrence, 
which took place between 12 and 14 wk after treatment. Quantifica-
tion of luminescence detected at different time points is shown in 
Figure 5b. The same results were achieved by applying the DMBA-
TPA protocol to the mouse ear. Representative images are shown at 
1, 2, 4, 5, 7, 10, 11, 12, and 14 wk after the first DMBA treatment 
(Figure 5c), and data are presented graphically in Figure 5d.
We next asked whether induction of luciferase expression upon 
induction of proliferation/regeneration is a general feature of MITO-
Luc mouse tissues. We analyzed the light emitted by skeletal muscle 
during regeneration following acute hind limb ischemia. This rapid 
repair process is mainly carried out by satellite cells (SCs) that be-
come active and proliferate upon injury (Zaccagnini et al., 2007). 
Unilateral hind limb ischemia was induced in MITO-Luc mice by re-
moving the femoral artery. As shown in Figure S6A, light emission 
decreased in the injured limb at 1 d postischemia, compared with 
the contralateral limb, which emitted light from the femur and bone 
marrow (Figure 1c). Of note, at 2, 4, and 7 d postischemia, adductor 
and gastrocnemius muscles from injured limb emitted light, as dem-
onstrated by in vitro luciferase assays in protein extracts from these 
posttreatment. Representative images are shown at 3, 6, 11, 15, 20, 
and 35 d posttreatment (Figure 3d). At 3 d posttreatment, luciferase 
activity was inhibited in the entire body, indicating that both radia-
tion doses induced tissue damage. At 11 and 20 d, in mice treated 
with 3 and 5 Gy, respectively, we observed an increase of luciferase 
activity, indicating that tissue repair mediated by proliferation was 
occurring at those times. In both cases, luminescence declined to 
the baseline until 35 d posttreatment. Taken together, these data 
strongly support the idea that luciferase activity maps whole-body 
proliferation events in MITO-Luc mice.
Luciferase activity is high in proliferating cells derived 
from MITO-Luc mice
We observed high luciferase activity in MITO-Luc mouse embryos at 
19 d postcoitum (dpc; Figure 4a). Luciferase activity was analyzed in 
embryonic tissues at 19 dpc and found present in all, although to 
different extents (Figure 4b). Since cell proliferation is widespread in 
embryonic tissues, these results support the hypothesis that NF-Y 
activity in intact animals correlates with this process. We have previ-
ously demonstrated that NF-Y exerts its transcriptional activity in 
primary proliferating myoblasts and fibroblasts but is inactive in ter-
minally differentiated myotubes and quiescent fibroblasts (Gurtner 
et al., 2008). We asked whether NF-Y was active in primary prolifer-
ating myoblasts from MITO-Luc mice. Figure 4c shows that luciferase 
activity is high in primary myoblasts obtained from skeletal muscles 
of newborn MITO-Luc mice, while it is shut down in terminally dif-
ferentiated myotubes. As a control for proliferation, myoblasts and 
myotubes were cultured for 24 h in the presence of BrdU, a marker 
FIGURE 3: Analysis of luciferase activity upon inhibition of proliferation in MITO-Luc mice. 
(a) In vitro luciferase activity and (b) FACS analysis of MITO-Luc mouse bone marrow 5 d after 
treatment with 5-FU antiproliferative drug (150 mg/kg). Error bars represent the deviation of 
the mean of bone marrow from three animals. (c) BLI of a representative MITO-Luc mouse 
before (NT) and after (5, 10, 15, 23, 30, and 75 d) treatment with 5-FU (150 mg/kg). The 
experiments were conducted in five animals. (d) BLI of a representative MITO-Luc mouse before 
(NT) and after (3, 6, 11, 15, 20, and 35 d) treatment with 3 or 5 Gy. The experiments were 
conducted in five animals. (c and d) Light emitted from the animal appears in pseudocolor 
scaling.
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antibodies against PCNA or luciferase showed significant overlap in 
the expression of both markers (Figure 6c).
Luciferase activity was not present in CCl4-treated MITO-LUC 
mouse liver pretreated with a cobra toxin, MCTX (Figure 6e), which 
impairs entry of hepatocytes into S phase. Moreover, Ad-dnYA injec-
tion in CCl4-treated mice strongly inhibited luciferase activation in 
liver, compared with luciferase activation observed in mice injected 
with an adenovirus carrying a wild-type NF-YA protein (Ad-NFYA), as 
demonstrated by in vivo (Figure 7a) and ex vivo (Figure 7b) BLI and 
in vitro experiments (Figure 7c). As expected, an empty adenovirus, 
used as a control, showed intermediate luciferase activation (unpub-
lished data). Of note, the Ad-dnYA effect was accompanied by a 
tissues (Figure S6B). Part of the light in this and the contralateral 
limb originated from the femoral bone marrow (Figure S6C).
Finally, we took advantage of a regeneration model after hepatic 
injury with carbon tetrachloride (CCl4) administration. During regen-
eration of mammalian liver, quiescent hepatocytes reenter the cell 
cycle and divide synchronously once or twice before returning to 
quiescence (Fausto, 2000). This process is concomitant with tran-
scriptional induction of several NF-Y target genes regulating cell 
proliferation, for example, members of the cyclin and cdk families. 
Using in vivo (Figure 6a), ex vivo (Figure 6b), and in vitro (Figure S7) 
BLI experiments, we observed that CCl4-induced liver injury resulted 
in transient luciferase activation in the liver of MITO-Luc mice, peak-
ing at 4 d after treatment and returning to almost basal level after 
6 d. Staining of adjacent slices from livers of CCl4-treated mice with 
FIGURE 4: Luciferase activity in MITO-Luc mouse embryos and 
derived cells. (a) BLI of a representative MITO-Luc embryo at 19 dpc. 
Both positive and negative littermates are shown. The luciferase 
activity is visualized in pseudocolor scaling. (b) in vitro luciferase activity 
in tissues of 19 dpc MITO-Luc embryos. Each bar represents the mean 
value ± SEM of three to six embryos. (c) In vitro luciferase activity in 
proliferating myoblasts (P) or terminal differentiated myotubes (TD) 
derived from newborn MITO-Luc mice. Immunofluorescence to detect 
MHC or BrdU incorporation is shown. Nuclei were visualized with 
DAPI. (d) Luciferase activity in proliferating (P) or quiescent (Q) 
MITO-Luc mouse embryonic fibroblasts. Percentage of cell cycle phase 
distribution of P and Q cells is reported. Values are the mean of two 
experiments performed in triplicate.
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FIGURE 5: Luciferase activity in MITO-Luc mouse–induced 
papillomas. (a) BLI of a representative MITO-Luc mouse after 2, 4, 6, 
and 8 wk of DMBA-TPA treatments on ventral skin. (b) Quantification 
of emitted light from MITO-Luc mouse skin papillomas. The sites on 
the ventral surface of the animals in which the vehicle and the 
DMBA-TPA drugs have been spotted are indicated. (c) BLI of a 
representative MITO-Luc mouse after 1, 2, 4, 5, 7, 10, 11, 12, and 14 
wk of DMBA-TPA treatments on mouse ear. (d) Quantification of 
emitted light from MITO-Luc mouse ear papillomas. (a and c) Light 
emitted from the animal appears in pseudocolor scaling. (b and d) 
Photon emission from the lesions (black square) and from the 
contralateral part (white circle) measured as photons per second (p/s). 
Each bar represents the mean value ± SEM of four animals.
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lowing NF-Y transcriptional activity in vivo. 
Notably, the fact that NF-Y activity is exerted 
only in proliferating cells provides the un-
precedented ability to follow physiological 
and/or pathological proliferation in every 
body area of these mice. Specifically, we ob-
served by in vivo, ex vivo, and in vitro experi-
ments that luciferase activity in adult mice is 
high in tissues containing proliferating cells, 
while tissues that do not show luciferase ac-
tivity are mainly constituted by growth-ar-
rested and/or postmitotic cells.
The pattern of luciferase activity in MITO-
Luc reporter mice appears to be highly sta-
ble and reproducible. Indeed, from F1 to the 
current F13 generation, we have imaged 
∼300 mice and no differences have been ob-
served. Thus MITO-Luc mice appear to be a 
reproducible system for imaging prolifera-
tion events in vivo. However, our ex vivo ex-
periments indicate that some luminescence 
is lost due to tissue penetration. In addition 
to attenuation of light by overlying tissues, 
BLI is decreased by fur pigmentation. All BLI 
experiments shown here were performed 
after removal of fur with a depilatory agent. 
We have now bred MITO-Luc mice into FVB 
mice, and in this new animal model, we have 
been able to reproduce the phenotype ob-
served in C57BL/6 mice without removing 
the fur (Manni, personal communication). In-
terestingly, we have demonstrated that the 
number of proliferating cells, counted as 
PCNA-positive cells, parallels photon emis-
sion in vivo (Figure 6d). We now have pre-
liminary results on the sensitivity of this re-
porter system that indicate BLI detects 
proliferation events in MITO-Luc mice more 
efficiently than does staining with a marker 
of cell proliferation (unpublished data).
Induction of luciferase activity occurs in 
MITO-Luc mice tissues when proliferation is 
induced. As proof of principle, we induced 
skin papillomas in MITO-Luc mice, and we 
detected luminescence at the treated sites several days before tumor 
appearance, which indicates that the MITO-Luc animal model will al-
low study of early tumor development by noninvasive imaging tech-
niques. Moreover, we demonstrated that proliferation events during 
muscle regeneration after femoral ischemia, as well as during liver 
regeneration after drug injury, are detectable by the IVIS Imaging 
System. Thus we now have evidence not only in culture cells but also 
in intact animals that the NF-Y complex exerts its activity in proliferat-
ing cells and not in postmitotic ones. Moreover, using a dominant-
negative protein of NF-Y, we demonstrated for the first time that not 
only is NF-Y activity induced during liver regeneration after drug in-
jury, but it is also essential for it.
Many pathological and physiological processes involve changes in 
cell proliferation. For the most part, this has been followed at the tis-
sue and cellular level in collected samples. Recently the generation of 
the Fucci system (Sakaue-Sawano et al., 2008) enabled cell cycle anal-
ysis to be efficiently carried out at the organismal level. However, this 
again is restricted to nonvital samples, and the utility of this model for 
strong reduction of a well-known NF-Y target gene, cyclin A, during 
cell cycle progression, demonstrating that the luciferase inhibition in 
the liver of Ad-dnYA–injected mice is due to inhibition of prolifera-
tion (Figure 7d). These results indicate that induction of lumines-
cence strictly correlates with induction of proliferation in MITO-Luc 
mice and strongly suggest that NF-Y activity is essential for hepato-
cyte proliferation during liver regeneration in intact animals.
DISCUSSION
In the present study, we generated a reporter transgenic mouse 
model in which, using the activity of the master regulator of prolifera-
tion, NF-Y, it is possible to visualize proliferation in intact animals. As 
a sensor of NF-Y transcriptional activity, we used a cyclin B2 promoter 
fragment to drive the transcription of the luciferase gene. We dem-
onstrated that luciferase activity is strictly NF-Y–dependent by using 
a dominant-negative protein for NF-Y that completely abolishes lu-
ciferase activity in these mice. Thus the new transgenic mouse model, 
called MITO-Luc reporter mouse, is an unprecedented tool for fol-
FIGURE 6: Luciferase activity during MITO-Luc mouse tissue regeneration. (a) BLI of a 
representative MITO-Luc mouse after 1, 4, and 6 d of CCl4-induced liver damage. After fur 
removal in the ventral region, the images were collected in a ventral close-range mode. (b) Ex 
vivo optical imaging of a MITO-Luc mouse liver damaged by CCl4. (c) Immunohistochemical 
analysis of PCNA and luciferase (LUC) in liver tissue from a representative MITO-Luc mouse 
damaged by CCl4. Images were collected at 40× (insets: 100×). (d) Quantification of PCNA-
positive nuclei in liver tissue sections (left graph) and quantification of liver photon emission 
(right graph) at days 4 and 6 after liver injury. Error bars indicate the deviation of the mean of 
two experiments performed in triplicate. (e) BLI of a representative MITO-Luc mouse after 1, 4, 
and 6 d of treatment with MCTX and CCl4. (a, b, and e) Experiments were conducted in five 
animals per group.
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C57BI/6xDBA/2 eggs using a standard pro-
tocol (Hogan et al., 1994). Injected zygotes 
were reimplanted into pseudopregnant 
B6D2F1 (C57Bl/6xDBA/2) foster mothers 
to complete their development. The lin-
eages were maintained in the heterozygous 
state. After genomic DNA extraction of tail 
biopsies (Ciana et al., 2003), the positive 
founder animals were identified by PCR 
using the following primers specific for 
the transgene: oligonucleotide up: 5′- 
TGTAGACAAGGAAACAACAAAGCCTG-
GTGGCC; and oligonucleotide down: 
5′-GGCGTCTTCCATTTTACCAACAGTAC-
CGG.
In vivo and ex vivo BLI
Light emission was detected using the IVIS 
Lumina II CCD camera system and analyzed 
with the Living Image 2.20 software pack-
age (Caliper Life Sciences). Mice were anes-
thetized and 150 or 75 mg/kg of d-luciferin 
was injected intraperitoneally. Ten minutes 
later, quantification of light emission was 
performed in photons/second and visual-
ized in a pseudocolor scaling. Time expo-
sure ranged from 1 to 5 min, depending on 
light intensity.
Luciferase assay from tissue extracts
After tissue dissection, the organs were im-
mediately frozen on dry ice. Bone marrow 
was flushed out from the femur and tibia, as 
previously described (Gurtner et al., 2010). 
Tissue extracts were prepared by homoge-
nization in a 100 mM KPO4 lysis buffer (pH 
7.8) containing 1 mM dithiothreitol, 4 mM 
ethylene glycol tetraacetic acid, 4 mM 
EDTA, and 0.7 mM phenylmethylsulfonyl 
fluoride. After three freeze-thaw cycles, the 
extracts were centrifuged, the supernatants were collected, and the 
protein concentration was determined by Bradford’s assay. Luc as-
say was performed according to Manni et al. (2001). The values were 
normalized for β-galactosidase expression and/or protein amounts.
Immunohistochemistry
Serial sections of MITO-Luc mice tissues were prepared as previ-
ously described (Gurtner et al., 2003). Primary antibodies were: 5 
μg/100 μl anti–NF-YA (Rockland), 2 μg/100 μl anti-PCNA 19A2 
(Beckman Coulter, Brea, CA), and an anti-luciferase (1:1800 dilution 
in phosphate-buffered saline with 10% goat serum and 0.3% Triton 
[Sigma-Aldrich, St. Louis, MO]). Sections were processed following 
the manufacturer’s instruction of the UltraTek HRP Anti-Polyvalent 
(DAB) Staining System (Scytek). Peroxidase activity of the tertiary 
antibodies was visualized by reaction with 3,3′-diaminobenzidine 
and H2O2 in sodium phosphate buffer (Vector Laboratories, Burl-
ingame, CA). The sections were stained with hematoxylin.
Cell culture and transfections
C2C12 cells were cultured and transiently transfected as previously 
described (Manni et al., 2001). Primary myoblasts were isolated from 
mouse embryos and maintained and induced to differentiate 
studying cell proliferation in adult animals has not been shown, 
whereas the mouse model we have developed enabled monitoring of 
cell proliferation in live animals. MITO-Luc mice crossed with animal 
disease models will allow study of aberrant proliferation in a given 
pathogenesis in the entire animal. Further, MITO-Luc mice will enable 
cancer imaging during and after therapy and will open up new possi-
bilities for the study in live organisms of drugs affecting proliferation.
MATERIALS AND METHODS
Plasmid generation
We used a described vector, pHS4, for the generation of the MITO-
Luc reporter constructs (Ciana et al., 2003) using standard cloning 
procedures. The constructs, pHS4wtB2-luc and pHS4mutB2-luc, 
were obtained by cloning a murine cyclin B2 promoter fragment 
into the NdeI and BglII sites of the pHS4 plasmid. This murine cyclin 
B2 promoter fragment spans the –266 to +46 base-pair region with 
respect to the transcription start site in front of a luciferase reporter 
with wild-type or mutant NF-Y–binding sites.
Generation and genotyping of the transgenic mice
The transgene was isolated from the vector backbone, and the 
purified fragment was injected into pronuclear DNA of fertilized 
FIGURE 7: NF-Y activity during liver regeneration. (a) BLI of a representative MITO-Luc mouse 
after CCl4-treatment and intravenous injection of Ad-NFYA or Ad-dnYA. Experiments were 
conducted in six animals per group. (b) Ex vivo BLI of representative MITO-Luc mouse livers 
after intravenous injection of Ad-NFYA or Ad-dnYA and CCl4 treatment at the indicated time 
points. (c) In vitro luciferase activity in liver after intravenous injection of Ad-NFYA or Ad-dnYA 
and CCl4 treatment. Each bar represents the mean value ± SEM of three animals. (d) Western 
blot analysis of cyclin A expression in livers from MITO-Luc mice after CCl4-treatment and 
intravenous injection of Ad-NFYA or Ad-dnYA. β-actin has been used as loading control.
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(myotubes) in culture as previously described (Gurtner et al., 2008). 
MEFs were isolated and cultured from 13.5-d-old embryos as previ-
ously described (Gurtner et al., 2010).
Cell cycle analysis
DNA distribution analysis of propidium iodide–stained cells was 
performed according to standard procedures. A total of 104 events 
were analyzed by a cytofluorometer (Beckman Coulter). Cell cycle 
distribution was determined using computer-assisted analysis 
(M-cycle software).
Pharmacological and surgical treatments
Ventral and ear skin papillomas were generated following a DMBA-
TPA protocol. Briefly, mice were treated with a single topical applica-
tion of 860 μM DMBA (Sigma-Aldrich) in 0.2 ml acetone or with the 
solvent alone on their shaven skin or ears. One week after, 100 μM 
of TPA (Alexis Biochemicals, San Diego, CA) in 0.2 ml acetone or the 
solvent alone was topically applied twice-weekly to the skin or ears. 
The surgical procedure for creating unilateral hind limb ischemia was 
performed according to Zaccagnini et al. (2007). Acute hepatic injury 
was obtained by intraperitoneal single injection of CCl4 (1 ml/kg; 
Sigma-Aldrich) dissolved in peanut oil (Pilichos et al., 2004). Mono-
crotaline (MCTX; Sigma-Aldrich) treatment was performed accord-
ing to standard procedures (Witek et al., 2005). The recombinant 
adenovirus vectors expressing green fluorescent protein (GFP), 
NFYA, and dn-YA (Gurtner et al., 2008) were injected into the tail 
vein in adult mice. Mice were treated intravenously with 150 mg/kg 
of 5-FU (Teva Pharma Italia, Milan Italy). For irradiation experiments, 
mice were placed in the chamber and whole-body-irradiated with 
3–5 Gy of γ-rays from a CIS BioInternational IBL 437C 137Cs gamma.
Immunofluorescence
Cells were stained with Anti-BrdU (clone B44; BD Bioscience) and 
MHC (mouse hybridoma; Magenta et al., 2003) primary antibodies 
and Cy3- and Cy5-conjugated donkey anti-mouse as secondary an-
tibodies (Jackson ImmunoResearch, West Grove, PA). Nuclei were 
stained with 4′,6-diamidino-2-phenylindole (DAPI; 33258; Sigma-
Aldrich).
Experimental animals
Animal experiments performed in this study were conducted ac-
cording to the “Guidelines for Care and Use of Experimental Ani-
mals” and the Italian law DL 116/92.
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